Summit Therapeutics PLC (SMMT)
NASDAQ:SMMT
Want to see SMMT full AI Analyst Report?
SMMT Stock Chart & Stats
$25.15
$0.42(2.31%)
At close: 4:00 PM EST
$25.15
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$13.83 - $30.98
Previous CloseN/A
Volume1.23M
Average Volume (3M)4.85M
Market Cap
$11.53B
Enterprise Value$13.53B
Total Cash (Recent Filing)$454.05M
Total Debt (Recent Filing)$15.20M
Price to Earnings (P/E)―
Beta2.66
Next Earnings
Aug 12, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding776,162,660
10 Day Avg. Volume4,368,212
30 Day Avg. Volume4,851,710
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.77
Forecast
1Y Price Target
$31.20Price Target Upside24.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$3.72M
Bulls Say, Bears Say
Bulls Say
Clinical Data: Ivonescimab Phase IIRobust interim Phase II results with high ORR, complete disease control and durable responses materially strengthen the clinical story for ivonescimab. This reinforces its differentiated PD‑1/VEGF bispecific profile, supports Phase III execution and raises the program's long‑term commercial potential if confirmed.
Low Financial LeverageRelatively low leverage and a meaningful equity base improve solvency and give the company more strategic flexibility than highly levered peers. This reduces immediate default risk and lengthens potential runway, supporting continued clinical investment and partner negotiations over the coming months.
Management Alignment & Liquidity SupportAuthorization for affiliate and insider purchases signals board and management alignment with shareholders and creates a structural channel for liquidity support. Such programs can help stabilize share liquidity and provide a non-dilutive or less-dilutive mechanism to support financing and market functioning over time.
Bears Say
Severe Cash BurnDeep and accelerating negative free cash flow places persistent pressure on liquidity and forces reliance on external financing. Continued high burn increases dilution risk, constrains optionality for new programs, and creates structural funding uncertainty across the next several quarters absent material partner payments or financing.
Minimal Revenue BaseLack of commercial revenue eliminates internal cash generation and prevents operating leverage. The business remains entirely dependent on milestone/collaboration payments or financings, so long‑term sustainability hinges on successful development and partner commercialization rather than recurring sales.
Widening Net Losses & Funding RiskSubstantial year‑over‑year increase in net losses indicates stepped‑up spending and/or one‑off charges, accelerating equity depletion and elevating financing needs. Combined with historical volatility in leverage, this raises execution and dilution risk if clinical or partnership milestones slip.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics PLC’s price range in the past 12 months?
Summit Therapeutics PLC lowest stock price was $13.83 and its highest was $30.98 in the past 12 months.
What is Summit Therapeutics PLC’s market cap?
Summit Therapeutics PLC’s market cap is $11.53B.
When is Summit Therapeutics PLC’s upcoming earnings report date?
Summit Therapeutics PLC’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were Summit Therapeutics PLC’s earnings last quarter?
Summit Therapeutics PLC released its earnings results on Apr 30, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.269 by $0.029.
Is Summit Therapeutics PLC overvalued?
According to Wall Street analysts Summit Therapeutics PLC’s price is currently Undervalued.
Does Summit Therapeutics PLC pay dividends?
Summit Therapeutics PLC does not currently pay dividends.
What is Summit Therapeutics PLC’s EPS estimate?
Summit Therapeutics PLC’s EPS estimate is -0.28.
How many shares outstanding does Summit Therapeutics PLC have?
Summit Therapeutics PLC has 776,162,660 shares outstanding.
What happened to Summit Therapeutics PLC’s price movement after its last earnings report?
Summit Therapeutics PLC reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.269. Following the earnings report the stock price went down -24.907%.
Which hedge fund is a major shareholder of Summit Therapeutics PLC?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.20 (24.06% Upside)
$31.20 (24.06% Upside)
Blogger Sentiment
Neutral
SMMT Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Negative
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.16%
12-Months-Change
Fundamentals
Return on Equity
-340.55%
Trailing 12-Months
Asset Growth
68.79%
Trailing 12-Months
Company Description
Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong set of clinical and operational achievements: multiple positive Phase III readouts, broad global development, robust patient exposure, strategic collaborations, a healthy cash balance ($713.4M), manufacturing transfer to the U.S., and an accepted BLA with a November 14, 2026 PDUFA date. Key risks remain around demonstrating statistically significant overall survival for U.S. approval in the EGFR setting, OS immaturity at the interim PFS readout for HARMONi-3 squamous, increased near-term R&D spending (non-GAAP op expenses +~9.6% Q/Q), and reliance on partner-generated data from China which may require bridging for global regulatory bodies. On balance, the highlights (clinical momentum, approvals in China, partnerships, cash runway, manufacturing readiness) outweigh the challenges, but the path to full U.S. approval and broader commercialization depends on forthcoming OS data and regulatory interactions.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$31.20
▲(24.06% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---